Wedbush Predicts Reduced Earnings for Telix Pharmaceuticals

Telix Pharmaceuticals Limited (NASDAQ:TLX) – Stock analysts at Wedbush dropped their FY2025 earnings estimates for Telix Pharmaceuticals in a research note issued on Tuesday, October 14th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($0.11) for the year, down from their prior forecast of $0.06. Wedbush currently has a “Outperform” rating and a $22.00 target price on the stock. The consensus estimate for Telix Pharmaceuticals’ current full-year earnings is $0.24 per share. Wedbush also issued estimates for Telix Pharmaceuticals’ FY2027 earnings at $0.39 EPS.

Several other equities research analysts have also recently commented on the stock. Canaccord Genuity Group raised shares of Telix Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 6th. Citigroup started coverage on shares of Telix Pharmaceuticals in a research report on Thursday, September 18th. They issued a “buy” rating and a $22.00 price objective on the stock. HC Wainwright cut their price objective on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, September 10th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 28th. Finally, UBS Group cut their price objective on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating on the stock in a research report on Tuesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $21.00.

Telix Pharmaceuticals Price Performance

Shares of NASDAQ TLX opened at $10.86 on Thursday. Telix Pharmaceuticals has a twelve month low of $8.93 and a twelve month high of $30.36. The company’s fifty day moving average is $10.31 and its 200-day moving average is $14.16.

Institutional Investors Weigh In On Telix Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Pier Capital LLC acquired a new stake in Telix Pharmaceuticals in the 2nd quarter valued at $3,037,000. Russell Investments Group Ltd. acquired a new stake in Telix Pharmaceuticals in the 2nd quarter valued at $975,000. Jane Street Group LLC acquired a new stake in Telix Pharmaceuticals in the 2nd quarter valued at $564,000. ABC Arbitrage SA acquired a new stake in Telix Pharmaceuticals in the 1st quarter valued at $451,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in Telix Pharmaceuticals in the 2nd quarter valued at $297,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.